Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28 mars 2024 08h00 HE
|
Cocrystal Pharma, Inc.
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
19 mars 2024 08h00 HE
|
Cocrystal Pharma, Inc.
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash., March 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or...
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
04 janv. 2024 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides an update on the clinical development of its oral first-in-class...
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
29 nov. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its...
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023
27 nov. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive...
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
13 nov. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to begin later this year in Phase 2a human...
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast
09 nov. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces that President and co-CEO Sam Lee, PhD will discuss progress in...
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
31 oct. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare...
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus
28 sept. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its...
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
05 sept. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel...